Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hodgkin's Lymphoma: early-phase trial registry
4 of 19 indexed Hodgkin's Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #902 of 28,707 conditions by registered trial count.
19 US clinical trials · 4 currently recruiting · #902 of 28,707 conditions by registered trial count
Hodgkin's Lymphoma: 19 US clinical trials tracked, 4 recruiting.
Hodgkin's Lymphoma is the subject of 19 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition hodgkins-lymphoma
OPEN 4 | RECR 21% | LATE 0 | EARLY 17 | RANK #902 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Ocular Hypertension (21% recruiting · 57 trials)
Hodgkin's Lymphoma lists 4 open slots (21% of 19 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hodgkin's Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hodgkin's Lymphoma is recruiting below its size-band peers.
4 of 19 indexed trials (21.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hodgkin's Lymphoma research.
Memorial Sloan Kettering Cancer Center accounts for 3 of 19 trials (15.8%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Hodgkin's Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 19 trials that report a genuine target (sentinel values excluded). 14 of those (73.7%) plan for fewer than 100 participants.
-
Hodgkin's Lymphoma research is mostly interventional.
17 interventional and 2 observational studies make up this index (89.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
19 total, page 1 of 1
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
Memorial Sloan Kettering Cancer Center
NCT01788839
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Baylor College of Medicine
NCT02917083
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
M.D. Anderson Cancer Center
NCT05355051
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health
NCT05589896
Communication Skills Intervention to Promote Transition Into Survivorship
Memorial Sloan Kettering Cancer Center
NCT01483664
EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma
Baylor College of Medicine
NCT01192464
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
National Heart, Lung, and Blood Institute (NHLBI)
NCT02208037
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
Stanford University
NCT00388349
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Mundipharma Research Limited
NCT02576496
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
National Cancer Institute (NCI)
NCT00520130
Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma
Abbott
NCT00061672
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
Merck Sharp & Dohme
NCT04875195
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
NCT01508312
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
S*BIO
NCT00741871
Reduced Intensity Double Umbilical Cord Blood Transplantation
Massachusetts General Hospital
NCT01408563
Meloxicam vs Placebo for Mobilization
Massachusetts General Hospital
NCT02003625
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Northside Hospital
NCT02581007
Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation
West Virginia University
NCT01203020
Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients
TG Therapeutics
NCT02164006
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 10 |
Top Sponsors
Named interventions
Most-linked intervention names on Hodgkin's Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hodgkin's Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hodgkin's Lymphoma page
19 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Hodgkin's Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Hodgkin's Lymphoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hodgkin's Lymphoma condition card totals 19 registered trials; most-linked intervention Fludarabine; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.